Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 1.00 |
| ▸ | CNR2 | P34972 | 5/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delta-8-Tetrahydrocannabinol SCHEMBL31545578 | 1.00 | CNR1 (1.00) | CNR1CNR2KDR | |
| Delta-8-Tetrahydrocannabinol SCHEMBL120839 | 1.00 | CNR1 (1.00) | CNR1CNR2KDR | |
| Delta-8-Tetrahydrocannabinol SCHEMBL31545313 | 1.00 | CNR1 (1.00) | CNR1CNR2KDR | |
| Delta-8-Tetrahydrocannabinol SCHEMBL31315116 | 1.00 | CNR1 (1.00) | CNR1CNR2KDR | |
| Delta-8-Tetrahydrocannabinol SCHEMBL2800340 | 1.00 | CNR1 (1.00) | CNR1CNR2KDR | |
| Delta-8-Tetrahydrocannabinol SCHEMBL24237019 | 1.00 | CNR1 (1.00) | CNR1CNR2KDR | |
| Delta-8-Tetrahydrocannabinol SCHEMBL12054803 | 1.00 | CNR1 (1.00) | CNR1CNR2KDR | |
| Delta-8-Tetrahydrocannabinol SCHEMBL2762327 | 1.00 | CNR1 (1.00) | CNR1CNR2KDR | |
| Delta-8-Tetrahydrocannabinol SCHEMBL31236168 | 1.00 | CNR1 (1.00) | CNR1CNR2KDR | |
| Delta-8-Tetrahydrocannabinol SCHEMBL29361531 | 1.00 | CNR1 (1.00) | CNR1CNR2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 531 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | Doane Technology Group LLC (US) | 2026-05-26 | — | — | US | claimed |
| EP-4712952-A1 | SOLID CANNABINOID COMPOSITION FOR PARENTERAL USE | Bender Analytical Holding B.V. (NL) | 2026-03-25 | — | — | EP | claimed |
| EP-4161580-B1 | CANNABINOID-HYALURONIC ACID BIOCONJUGATES | LONDON PHARMACEUTICALS AND RES CORPORATION (CA) | 2026-03-18 | — | — | EP | claimed |
| EP-3894036-B1 | EXTRACTION METHOD | NATURALIA INGREDIENTS S R L (IT) | 2026-01-14 | — | — | EP | claimed |
| US-12491452-B2 | Extraction method and composition obtained therefrom | NATURALIA INGREDIENTS S.R.L. (IT) | 2025-12-09 | — | — | US | claimed |
| US-20250366505-A1 | AEROSOL-GENERATING SUBSTRATES AND ENCAPSULATED FLAVORANTS | ALTRIA CLIENT SERVICES LLC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250360176-A1 | CHEWING GUM CONTAINING SYNERGISTIC MEDICINAL COMPOUNDS | LONDON PHARMACEUTICALS AND RES CORPORATION (CA) | 2025-11-27 | — | — | US | claimed |
| WO-2025213224-A1 | TREATMENT OF KCNT1-RELATED DISORDERS | UNIVERSITY OF SOUTH AUSTRALIA (AU) | 2025-10-16 | — | — | WO | claimed |
| EP-4611740-A1 | CANNABINOID FORMULATIONS AND USE FOR TREATMENT OF EMOTIONAL DISORDERS AND SEXUAL DYSFUNCTION | Progressive Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| US-20250275935-A1 | COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S DISEASE WITH A COMBINATION OF THC AND MELATONIN | IGC PHARMA IP, LLC (US) | 2025-09-04 | — | — | US | claimed |
| US-20220242809-A1 | METHODS FOR ISOLATING ESSENTIAL OILS, PHYTOCHEMICALS AND PHARMACEUTICALLY ACTIVE COMPONENTS FROM BIOMASS AND RECONSTITUTING SYNTHETIC FORMULATIONS COMPRISING SAME | ATLAS HEMP COMPANY LLC (US) | 2022-08-04 | — | — | US | claimed |
| EP-4027971-A2 | ORALLY DISSOLVING MUCOADHESIVE FILMS UTILIZING MENTHOL AND L-ARGININE TO ENHANCE THE BIOAVAILABILITY OF CANNABINOIDS | Calitas Therapeutics, Inc. (US) | 2022-07-20 | — | — | EP | claimed |
| US-20220110911-A1 | CANNABINOID COMPOSITION AND PROCESSES OF MANUFACTURE | VIALPANDO, LLC (US) | 2022-04-14 | — | — | US | claimed |
| EP-3975703-A1 | PENETRATING TOPICAL PAIN RELIEF COMPOSITIONS AND METHODS OF USE | Tech Swerve LLC (US) | 2022-04-06 | — | — | EP | claimed |
| CN-111211577-B | Method for improving operation reliability of new energy in regional power grid subareas | 国网河南省电力公司电力科学研究院 | 2022-04-05 | — | — | CN | claimed |
| EP-3962457-A1 | CANNABINOID COMPOSITION AND PROCESSES OF MANUFACTURE | Vialpando, LLC (US) | 2022-03-09 | — | — | EP | claimed |
| US-11261477-B2 | Glycosylation modification of bioactive compounds and drugs by plant glycosyltransferases (UGTs) | UNIVERSITY OF NORTH TEXAS (US) | 2022-03-01 | — | — | US | claimed |
| EP-3955894-A1 | SELF-EMULSIFYING DRUG DELIVERY SYSTEMS FOR DELIVERY OF LIPOPHILIC COMPOUNDS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd (IL) | 2022-02-23 | — | — | EP | claimed |
| CN-112033336-B | Double-shaft arc type large-size involute sample plate measurement uncertainty analysis method | 北京工业大学 | 2022-02-15 | — | — | CN | claimed |
| US-20220023771-A1 | EXTRACTION METHOD AND COMPOSITION OBTAINED THEREFROM | NATURALIA INGREDIENTS S.R.L. (IT) | 2022-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | CNR2, CNR1, LIPC | CNR1 2/4885CNR2 1/4885KDR 2904/4885 |
| US-20250360176-A1 | CHEWING GUM CONTAINING SYNERGISTIC MEDICINAL COMPOUNDS | CNR2, CNR1, TAS2R60 | CNR1 2/4885CNR2 1/4885KDR 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.